Nothing Special   »   [go: up one dir, main page]

CY1111743T1 - Παραγωγα ν-υδροξυαμιδιου και η χρηση τους - Google Patents

Παραγωγα ν-υδροξυαμιδιου και η χρηση τους

Info

Publication number
CY1111743T1
CY1111743T1 CY20111100760T CY111100760T CY1111743T1 CY 1111743 T1 CY1111743 T1 CY 1111743T1 CY 20111100760 T CY20111100760 T CY 20111100760T CY 111100760 T CY111100760 T CY 111100760T CY 1111743 T1 CY1111743 T1 CY 1111743T1
Authority
CY
Cyprus
Prior art keywords
hydroxymide
products
diseases
fibrosis
emphysema
Prior art date
Application number
CY20111100760T
Other languages
English (en)
Inventor
Dominique Swinnen
Jerôme GONZALEZ
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of CY1111743T1 publication Critical patent/CY1111743T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182Radicals derived from carboxylic acids
    • C07D295/185Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D317/34Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με παράγωγα του Ν-υδροξυαμιδίου με τον Τύπο (I), με τη χρήση τους ιδιαίτερα για τη θεραπευτική αντιμετώπιση για και/ή την προφύλαξη από αυτοάνοσες διαταραχές, φλεγμονώδεις νόσους, καρδιαγγειακές νόσους, νευροεκφυλιστικές νόσους, καρκίνο, αναπνευστικές νόσους και ίνωση, μεταξύ των οποίων η σκλήρυνση κατά πλάκας, το εμφύσημα, η χρόνια αποφρακτική πνευμονική νόσος, η ηπατική και η πνευμονική ίνωση.
CY20111100760T 2005-01-31 2011-08-09 Παραγωγα ν-υδροξυαμιδιου και η χρηση τους CY1111743T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05100646 2005-01-31
US64893105P 2005-02-01 2005-02-01
EP06707864A EP1844032B1 (en) 2005-01-31 2006-01-27 N-hydroxyamide derivatives and use thereof

Publications (1)

Publication Number Publication Date
CY1111743T1 true CY1111743T1 (el) 2015-10-07

Family

ID=34938610

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100760T CY1111743T1 (el) 2005-01-31 2011-08-09 Παραγωγα ν-υδροξυαμιδιου και η χρηση τους

Country Status (25)

Country Link
US (2) US7868009B2 (el)
EP (1) EP1844032B1 (el)
JP (1) JP4950070B2 (el)
KR (1) KR20070105326A (el)
CN (1) CN101208320B (el)
AT (1) ATE516279T1 (el)
AU (1) AU2006208781B2 (el)
BR (1) BRPI0606756A2 (el)
CA (1) CA2592154C (el)
CY (1) CY1111743T1 (el)
DK (1) DK1844032T3 (el)
EA (1) EA014238B1 (el)
ES (1) ES2369093T3 (el)
HK (1) HK1115132A1 (el)
HR (1) HRP20110529T1 (el)
IL (1) IL184538A (el)
MX (1) MX2007009231A (el)
NO (1) NO20074458L (el)
PL (1) PL1844032T3 (el)
PT (1) PT1844032E (el)
RS (1) RS51957B (el)
SI (1) SI1844032T1 (el)
UA (1) UA86862C2 (el)
WO (1) WO2006079653A1 (el)
ZA (1) ZA200705623B (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080090759A1 (en) * 2004-08-30 2008-04-17 Robert Kokenyesi Methods and kits for predicting risk for preterm labor
ATE516279T1 (de) * 2005-01-31 2011-07-15 Merck Serono Sa N-hydroxyamidderivate und ihre verwendung
CA2791691A1 (en) 2010-03-03 2011-09-09 Teva Pharmaceutical Industries Ltd. Treatment of lupus nephritis using laquinimod

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE82916B1 (en) * 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
WO1994008943A1 (en) 1992-10-21 1994-04-28 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
GB9411598D0 (en) * 1994-06-09 1994-08-03 Hoffmann La Roche Hydroxamic acid derivatives
FR2762514B1 (fr) 1997-04-29 1999-10-22 Sanofi Sa Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
TW591026B (en) 1998-06-23 2004-06-11 Upjohn Co Inhibitors of alpha4beta1 mediated cell adhesion
US20020115689A1 (en) 1999-12-21 2002-08-22 Joanne Waldstreicher Combination therapy for treating neurodegenerative disease
EP1110957A1 (en) 1999-12-24 2001-06-27 Applied Research Systems ARS Holding N.V. Benzazole derivatives and their use as JNK modulators
AU2001248820A1 (en) 2000-04-28 2001-11-12 Shionogi And Co., Ltd. Thiazole and oxazole derivatives
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
AR033459A1 (es) 2001-04-05 2003-12-17 Aventis Pharma Inc Uso de (41-trifluorometilfenil)-amida del acido (z)-2-ciano-3-hidroxi-but-2-enoico para el tratamiento de la esclerosis multiple
JP4164031B2 (ja) 2002-02-14 2008-10-08 ファルマシア コーポレーション P38mapキナーゼのモジュレータとしての置換されたピリジノン
GB0204159D0 (en) 2002-02-22 2002-04-10 British Biotech Pharm Metalloproteinase inhibitors
GB0208176D0 (en) 2002-04-09 2002-05-22 Novartis Ag Organic compounds
NZ564626A (en) 2002-09-24 2009-08-28 Novartis Ag Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders
TWI291467B (en) 2002-11-13 2007-12-21 Millennium Pharm Inc CCR1 antagonists and methods of use therefor
KR20070046873A (ko) * 2004-07-26 2007-05-03 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. N-히드록시아미드 유도체 및 그의 용도
ATE516279T1 (de) 2005-01-31 2011-07-15 Merck Serono Sa N-hydroxyamidderivate und ihre verwendung

Also Published As

Publication number Publication date
DK1844032T3 (da) 2011-10-24
CA2592154A1 (en) 2006-08-03
US7868009B2 (en) 2011-01-11
CN101208320A (zh) 2008-06-25
JP4950070B2 (ja) 2012-06-13
ZA200705623B (en) 2008-09-25
EP1844032A1 (en) 2007-10-17
EP1844032B1 (en) 2011-07-13
UA86862C2 (en) 2009-05-25
US8198280B2 (en) 2012-06-12
SI1844032T1 (sl) 2011-09-30
AU2006208781B2 (en) 2011-12-08
WO2006079653A1 (en) 2006-08-03
EA200701636A1 (ru) 2007-12-28
US20080090838A1 (en) 2008-04-17
US20110086864A1 (en) 2011-04-14
PL1844032T3 (pl) 2011-09-30
AU2006208781A1 (en) 2006-08-03
ATE516279T1 (de) 2011-07-15
CN101208320B (zh) 2012-01-11
BRPI0606756A2 (pt) 2009-07-14
NO20074458L (no) 2007-10-31
IL184538A (en) 2013-02-28
CA2592154C (en) 2014-03-18
HRP20110529T1 (hr) 2011-08-31
JP2008528553A (ja) 2008-07-31
RS51957B (en) 2012-02-29
IL184538A0 (en) 2007-10-31
MX2007009231A (es) 2007-09-19
ES2369093T3 (es) 2011-11-25
KR20070105326A (ko) 2007-10-30
EA014238B1 (ru) 2010-10-29
HK1115132A1 (en) 2008-11-21
PT1844032E (pt) 2011-07-27

Similar Documents

Publication Publication Date Title
CY1109194T1 (el) Παραγωγα ν-υδροξυαμιδιου και η χρηση του
DK1951674T3 (da) Sulfonamidderivater og anvendelse deraf til modulation af metalloproteinaser
CY1119901T1 (el) Αναστολεις απομεθυλασων ιστονων
EA201001127A1 (ru) Производные пиридина
CY1119231T1 (el) Θειαδιαζολιδινοδιονες ως αναστολεις της gsk-3
CY1113324T1 (el) Υποκατεστημενα αμιδικα παραγωγα ως αναστολεις πρωτεϊνικων κινασων
CY1125169T1 (el) ΕΝΩΣΕΙΣ ΑΜΙΝΟΠΥΡΑΖΙΝΟ ΔΙΟΛΗΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΡΙ3Κ-γ
CY1110190T1 (el) Παραγωγα πιπεραζινυλιου χρησιμα στην αγωγη των νοσων στις οποιες μεσολαβει ο υποδοχεας gpr38
CY1111743T1 (el) Παραγωγα ν-υδροξυαμιδιου και η χρηση τους
CY1123320T1 (el) Ενωση πυραζολοθειαζολης και φαρμακο που την περιλαμβανει
CY1112088T1 (el) Παραγωγα ν-υδροξυαμιδης και η χρηση τους
NO20070820L (no) Oktahydropyrrolo (2,3,C)pyridin-derivanter og farmasoytisk anvendelse derav.
DK1828160T3 (da) Cykliske sulfonylaminoderivater og anvendelse deraf som MMP-hæmmere
CY1112367T1 (el) Κυκλικα παραγωγα σουλφονυλ αμινο και χρηση αυτων ως μμρ αναστολεων
UA88785C2 (en) N-hydroxyamide derivatives and use thereof